Gianluca Pettiti
HPAbout Gianluca Pettiti
Gianluca Pettiti, age 46, was appointed as an independent director of HP Inc. in February 2025 and is currently Executive Vice President and President, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific Inc. He holds an M.S. in Engineering from Politecnico di Torino and brings deep experience in global technology businesses, science, innovation, and digital/AI initiatives, with an international career across Europe, South America, China, and the United States .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Thermo Fisher Scientific Inc. | Executive Vice President | 2021–Present | Executive leadership spanning global businesses |
| Thermo Fisher Scientific Inc. | President, Life Sciences, Diagnostics and Applied | 2024–Present | Leads digital, AI, innovation initiatives |
| Thermo Fisher Scientific Inc. | Senior Vice President & President, Specialty Diagnostics | 2019–2021 | Led Diagnostics segment |
| Thermo Fisher Scientific Inc. | President, Biosciences | 2018–2019 | Business leadership in biosciences |
| Thermo Fisher Scientific Inc. | President, China | 2015–2017 | Country leadership in China |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Thermo Fisher Scientific Inc. | EVP; President, Life Sciences, Diagnostics and Applied | 2021–Present (President since 2024) | Operating executive; not a director |
| Butterfly Network, Inc. | Director (prior) | Not disclosed | Prior public company board service |
Board Governance
- HP Board committees: Finance, Investment and Technology (FIT) Committee and HR & Compensation (HRC) Committee; the Board lists him as an independent director .
- Committee scopes:
- FIT: Capital structure/allocation, treasury, M&A oversight, technology strategy, derivative/financial risk oversight; 4 meetings in FY2024 .
- HRC: Executive and director compensation, succession planning, leadership development, human capital, compensation risk oversight; 8 meetings in FY2024 .
- Independence: Board determined all nominees except the CEO are independent under NYSE and HP standards, including Pettiti .
- Attendance: The Board held 7 meetings in FY2024 and each incumbent director (serving during FY2024) attended ≥75% of aggregate Board and applicable committee meetings; Pettiti joined in February 2025 (post-FY2024) .
- Bylaw qualifications: Directors must not have been officers/directors of competitors within prior 3 years and must have no qualifying criminal proceedings; applied to nominees .
Fixed Compensation
| Component | Amount/Terms | Notes |
|---|---|---|
| Annual cash retainer | $105,000 | For non-employee directors (2024 Board Year) |
| Annual equity retainer | $220,000 | Fully vested RSUs; intended to align interests, not service-vested |
| Chair of Board cash retainer | $200,000 | Additional for Chair |
| Committee Chair fees (Audit) | $35,000 | Additional cash |
| Committee Chair fees (HRC) | $25,000 | Additional cash |
| Committee Chair fees (NGSR) | $20,000 | Additional cash |
| Committee Chair fees (Other) | $20,000 | Additional cash |
| Excess meeting fees | $2,000 per meeting (>10 per Board Year) | Board or committee meetings beyond 10 |
| Deferral options | Cash retainers/chair fees may be deferred; cash retainer may be taken in RSUs | Multiple directors elected deferrals or RSUs in FY2024 |
Pettiti and Yoon did not receive compensation during FY2024 due to their FY2025 appointments; Pettiti’s 2025 Board Year compensation should follow the program unless changed by the Board .
Performance Compensation
| Element | Structure | Performance Metrics |
|---|---|---|
| Director equity | Fully vested RSUs upon grant | None; director equity is not performance- or service-vested |
Other Directorships & Interlocks
| Company | Relationship | Potential Interlock/Conflict |
|---|---|---|
| Butterfly Network, Inc. | Prior public company board | No HP-related interlock disclosed |
| Thermo Fisher Scientific Inc. | Current operating executive | Board independence review found no material relationship impacting independence; transactions reviewed under policy . |
Expertise & Qualifications
- Deep expertise in global technology businesses, science, innovation, and AI/digital initiatives; international operating experience across multiple regions .
- Technical education: M.S. in Engineering, Politecnico di Torino .
Equity Ownership
- Director stock ownership guidelines: within 5 years of election, non-employee directors must hold HP stock equal to 5× the annual cash retainer; shares counted include direct/indirect holdings and deferred stock awards .
- Compliance status at FY2024 end: all directors with >5 years met guidelines; those with <5 years are on track based on current trading prices .
- Hedging/pledging prohibitions: Directors are prohibited from hedging, and with limited exceptions, pledging HP securities or holding in margin accounts .
Governance Assessment
- Positive signals:
- Independence affirmed; no material relationships impacting independent judgment per NYSE/HP standards .
- Committee assignments align with Pettiti’s operating/technology background and place him at the center of capital allocation, M&A, technology strategy (FIT), and human capital/compensation oversight (HRC) .
- Board refresh and skills mix: appointment alongside a technology/AI-focused director and a consumer leader supports strategic oversight in AI and innovation .
- Strong governance practices: independent Chair, majority-independent Board, annual elections, executive sessions, stockholder engagement, clawbacks, no poison pill .
- Say-on-pay support: 2024 say-on-pay approved by >91% of voted shares, indicating investor confidence in compensation governance .
- Watch items:
- Director equity is fully vested and not performance-based, typical for directors but reduces explicit “at-risk” alignment; monitor ownership guideline compliance over time .
- Pettiti’s concurrent Thermo Fisher executive role: Board’s independence review cleared him, but ongoing monitoring for related-party transactions is prudent; HP’s policy requires NGSR review for material transactions; no Pettiti-related transactions disclosed .
No RED FLAGS disclosed for Pettiti regarding related-party transactions, hedging/pledging, legal proceedings, or attendance shortfalls; independence and committee-only membership standards upheld .